Published in Cancer Weekly, November 14th, 2006
The colorimetric based ELISA test that was utilized by the Miraculins' research team was also able to produce results in a sample subset consistent with the diagnostic results observed when using mass spectrometry for detection. The successful measurement of the biomarker using an immunoassay marks the first time that Miraculins has used an alternative diagnostic...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.